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Abstract
Background: This study aimed to evaluate the clinical significance of cysteine-rich 61 (Cyr-61/CCN1) and
cyclooxygenase-2 (COX-2), and further explored their combined prognostic significance in gastric cancer.
Methods: This retrospective study examined the expressions of Cyr-61 and COX-2 in 82 surgically removed gastric
cancer specimens and 43 non-tumor gastric mucosa specimens by immunohistochemical staining to identify the
abnormal expression of Cyr-61 or COX-2 in gastric cancer. Crude survival curves were constructed by the
Kaplan-Meier method and Cox proportional hazards regression analysis was performed to confirm the prognostic
roles of Cyr-61/COX-2 as well as sex and histological grade.
Results: The expressions of Cyr-61 (p < 0.001) and COX-2 (p = 0.001) were both significantly up-regulated in gastric
cancer samples compared with non-tumor gastric mucosa samples. The high expression of Cyr-61 or COX-2 was
associated with invasion, lymph node metastasis, distant metastases, poor histological differentiation, advanced
TNM stage and lower 5-year survival rate (all p < 0.05). Both Cyr-61 and COX-2 high expressions [hazard ratio (HR) = 31.
8, 95 % confidence interval (CI) 4.09–246.8] was associated the higher risk of death during 5 years follow up than single
Cyr-61 high expression (HR = 4.1, 95 % CI 1.5–11.6) or COX-2 high expression (HR = 2.9, 95 % CI 1.06–7.8).
Conclusions: Cyr-61 and COX-2 expressions are associated with the progression of gastric cancer. Additionally,
combined expressions of Cyr-61 and COX-2 has a higher prognostic value than single expression.
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Background
Gastric cancer is one of the most prevalent and the sec-
ond leading cause of malignant diseases worldwide [1].
In spite of the gradually decreased incidence, approxi-
mately 700,000 mortalities annually are caused by gastric
cancer worldwide [2]. Although the treatments for gastric
cancer have been considerably developed, the prognosis of
patients with advanced cancer is still poor due to the high
rate of metastasis [3]. Therefore, it is still imperative to
identify the molecular markers for the prognostic evalu-
ation of gastric cancer.
Cysteine-rich 61 (Cyr-61/CCN1) is a member of the
connective tissue growth factor family (CCN), which
plays important roles in cell proliferation, adhesion,
migration, angiogenesis and apoptosis. Studies in recent
years have revealed the link between Cyr-61 expression
and multiple malignant tumors such as lung cancer [4],
breast cancer [5], pancreatic cancer [6], oral squamous
cell carcinoma [7] and glioma [8]. Cyr-61 has also been
implicated in the development and progression in gastric
cancer [9]. Moreover, Maeta et al. reported that Cyr-61
expression in gastric cancer was significantly related to
tumor stage, histological differentiation, depth of tumor
invasion, lymphatic and venous invasion, and lymph
node metastasis [10]. However, the prognostic signifi-
cance of Cyr-61 in gastric cancer has not been fully
determined.
Recent studies have shown that COX-2 highly
expressed in esophageal cancer [11], colorectal cancer
[12] and other malignant tumors of the digestive tract
such as gastric cancer [13]. A recent meta-analysis
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revealed that high COX-2 expression was associated
with an unfavorable overall survival of patients with gas-
tric cancer [14]. Lin et al. [15] further demonstrated that
the COX-2 was functionally linked to Cyr-61, and COX-
2 played an important role in Cyr-61-promoted invasion
and motility in gastric cancer. These studies prompt that
Cyr-61 and COX-2 may jointly function in the occurrence
and development of gastric cancer, and the prognostic
value of the combination of Cyr-61 and COX-2 may
higher than that of the single Cyr-61 or COX-2. Thus, in
the current study, we evaluated the clinical significance of
Cyr-61/COX-2 co-expression in determining the clinico-
pathologic features of gastric cancer and further explored
their combined prognostic significance.
Methods
Patients and tissue materials
This retrospective study was approved by the Ethics
Committee in the China Medical University, which con-
forms to the provisions of the World Medical Associa-
tion’s Declaration of Helsinki in 2013 [16]. Gastric cancer
specimens were obtained from 82 patients with primary
gastric cancer by gastrectomy at Shengjing Hospital of
China Medical University between 2003 and 2005. To
identify the abnormal expressions of Cyr-61 and COX-2
in gastric cancer, total 43 non-tumor gastric mucosa spec-
imens were collected as the control by Endoscopy during
same period. All patients had not undergone radiotherapy
or chemotherapy prior to surgery. The permission to use
the tissue materials without informed content was pro-
vided by the Ethics Committee of Shengjing hospital (no
2011113). The patients were followed up from the time of
surgery until June 2010. Terminal event includes death
caused by recurrence and metastasis of gastric cancer.
The clinicopathologic records of patients including diam-
eter of tumor, infiltration depth, lymph node metastasis,
distance metastasis, histological grade, and tumor node
metastasis (TNM) stage were collected.
Streptavidin-perosidase (S-P) immunohistochemical
staining
Immunohistochemical staining of biopsy specimens sur-
gically collected from primary gastric cancer tissues as
well as non-tumor gastric mucosa specimens was carried
out following manufacturer’s instruction (Fuzhou MaiXin
biotechnology Co., Ltd, Fuzhou, China.) [17]. Paraffin sec-
tions of tissues were processed and rehydrated in xylene.
Slides were incubated in 3 % hydrogen peroxide solution
for 10 min to block endogenous peroxidase activity. Anti-
gen retrieval was performed by high temperature and
pressure (in EDTA, PH 9.0). Then, slides were blocked by
serum, incubated with 1:200 diluted anti-Cyr-61 antibody
(Abcam, UK) or 1:100 diluted anti-COX-2 antibody
(Boaosen, China) at 4 °C overnight. Phosphate Buffer
solution was used to replace the primary antibody in the
negative controls. After further incubation with appropri-
ate secondary antibody followed by the incubation with
streptavidin-perosidase method, slides were stained with
diaminobenzidine (DAB) and hematoxylin, dehydrated
and sealed.
Positive staining of Cyr-61 and COX-2 was determined
by the detection of brown particles in the cytoplasm
under a binocular light microscope (Nikon, Eclipse
E100). Staining results were divided into the following
category based on percentage of positive cells in total
cells: < 25 % as low expression and ≥ 25 % as high ex-
pression [18]. Based on this category, the patients with
gastric cancer were divided into Cyr-61 or COX-2 high
and low expression groups, in order to explore the rela-
tionship of these two proteins with clinicopathologic fea-
tures of gastric cancer as well as evaluate the prognostic
value of these two proteins. Six specimens were assessed
for each patient with a homogeneous staining.
Statistical analysis
Data analysis was performed by using SPSS 17.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Expression of Cyr-
61 and COX-2 between gastric carcinoma tissues and
non-tumor tissues as well as clinicopathologic features
between low and high expressions of Cyr-61/COX-2
groups were compared by Fisher test. Crude survival
curves were constructed by the Kaplan-Meier method
and survival rates between low and high expression of
Cyr-61/COX-2 groups were compared by the log-rank
test. To confirm the prognostic roles of Cyr-61 and
COX-2, cox proportional hazards regression analysis
with a enter method was used to calculate the hazard ra-
tio (HR) with adjustment by sex and histological grade




A total of 82 cancer patients were enrolled in our study,
including 58 (70.73 %) males and 24 (29.27 %) females.
The average age of the whole cohort was 55.61 years,
with a range from 25 to 79 years. Of the 82 patients, 31
cases were well differentiated and 51 were poorly differ-
entiated. The number of these patients with T1-T4 stage
of gastric cancers was 4, 24, 25 and 29, respectively; the
number of patients with TNM stage I-IV was 19, 13, 25
and 25, respectively. Fifty-six cases had lymph node me-
tastasis and 23 had distant metastasis. Finally, a total of
55 patients (31 males, 14 females) were completely
followed-up. These 55 patients were aged 25–79 years
(average age of 67.64 years).
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Cyr-61/COX-2 expression between gastric cancer and
non-tumor gastric mucosa
Immunohistochemical staining revealed that Cyr-61 ex-
pression levels in gastric cancer tissues was increased
compared with non-tumor gastric mucosa tissues, and
which were enhanced with the decrease of the degree of
gastric cancer differentiation (Fig. 1). Among the total
82 gastric cancer samples, 50 (60.98 %) exhibited high
expression of Cyr-61 (Table 1). By contrast, only 34.88 %
(15/43) of non-tumor gastric mucosa group displayed
high expression of Cyr-61 (Table 1). As shown in Table 1,
the difference in expression of Cyr-61 between gastric
cancer and non-tumor gastric mucosal tissues was sig-
nificant (p = 0.008). In addition, COX-2 expression levels
had a similar trend with the expression of Cyr-61 (Fig. 2).
Fifty-one (62.2 %) gastric cancer tissues showed high
expression of COX-2, while only 18 (41.86 %) of non-
tumor gastric mucosa tissues displayed high expression
of COX-2 (Table 1). There was significant difference in
COX-2 expression between gastric cancer and non-
tumor gastric mucosa specimens (p < 0.038) (Table 1). A
total of 37 out of 82 gastric cancer tissues showed high
expressions of both Cyr-61 and COX-2, while 18 exhib-
ited both low expressions, with a coincidence rate of
67.07 % [(37 + 18)/82].
Cyr-61/COX-2 expression level and clinical characteristics
of patients with gastric cancer
Further analyses found that the expression of Cyr-61
was closely associated with invasion depth (p = 0.027),
lymph node metastasis (p = 0.001), distant metastases
(p = 0.045), poor histological differentiation (p = 0.031),
and advanced TNM staging (p = 0.009). However, the
expression level of Cyr-61 was not related to the
diameter of tumor (p = 0.190), or gender (p = 0.752)
(Table 2). In addition, COX-2 expression was significantly
related to the diameter of tumor (p = 0.003), invasion
depth (p < 0.001), lymph node metastasis (p < 0.001),
distant metastases (p = 0.017), poor tissue differentiation
(p = 0.015), and advanced TNM staging (p < 0.001), but
not the gender of patients (p = 0.971) (Table 2).
Prognostic role of Cyr-61/COX-2 expression in survival of
gastric cancer patients
Of the whole cohort, the 5-year survival rate of patients
with high Cyr-61 expression was 11.4 %, while that of
the patients with low Cyr-61 expression was 75.0 %. The
5-year survival rate of patients with high levels of COX-
2 expression was 9.4 %, while the survival rate of the
patients with low COX-2 expression was 69.60 %. In
addition, the 5-year survival rate of patients with high
Fig. 1 Cyr-61 expression levels in gastric cancer tissues and non-tumor gastric mucosa tissue. Positive staining was mainly located in the cytoplasm of
the cells. a. negative expression in non-tumor mucosa; b. positive expression in well-differentiated gastric cancer; c. positive expression in moderately
differentiated gastric cancer; d. strong positive expression in poorly differentiated gastric cancer
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expressions of both Cyr-61 and COX-2 was 3.8 %, while
that of the patients with low expressions of both Cyr-61
and COX-2 was 92.3 %. Furthermore, Kaplan–Meier
curves of the Cyr-61 or COX-2 high expression and low
expression are shown in Fig. 3a, b, with p < 0.001 con-
sistently, demonstrating that the expression of Cyr-61 or
COX-2 was associated with the survival time of gastric
cancer patients. Also, Kaplan–Meier curve stratified by
the combined expressions of Cyr-61 and COX-2 demon-
strated high expressions of both Cyr-61 and COX-2
showed the shortest survival time of gastric cancer pa-
tients, while low expressions of both Cyr-61 and COX-2
showed the longest survival time of gastric cancer pa-
tients (p < 0.001, Fig. 3c).
To confirm the prognostic role of Cyr-61 or COX-2,
the Cox proportional hazards regression models were
adopted. Meanwhile, the other factors (including gender
and histological grade) were also analyzed for exploring
additional prognostic factors. The univariate analyses
demonstrated that histological grade (p = 0.031), Cyr-61
expression (p < 0.001), COX-2 expression (p < 0.001),
and the combined expressions of Cyr-61 and COX-2
(p = 0.001) were all significantly associated with the
survival of gastric cancer patients.
Further multivariate analyses demonstrated that Cyr-61
expression (p = 0.008), COX-2 expression (p = 0.039), and
the combined expressions of Cyr-61 and COX-2 (p =
0.003) were prognostic factors independent of gender and
histological grade (Table 3). Moreover, both Cyr-61 and
COX-2 high expressions [HR = 31.8 (4.1–246.8)] were
associated the higher risk of death during 5 years follow
up than Cyr-61 high expression [HR = 4.1 (1.5–11.6)] or
COX-2 high expression [HR = 2.9 (1.06–7.8)] only.
Discussion
In the present study, we examined the expression of
Cyr-61 and COX-2 in 82 gastric cancer specimens and
Fig. 2 COX-2 expression levels in gastric cancer group and non-tumor gastric mucosa group. Positive staining was mainly located in the cytoplasm of
tumor cells. a. negative expression in non-tumor mucosa; b. positive expression in well-differentiated gastric cancer; c. positive expression in moderately
differentiated gastric cancer; d. strong positive expression in poorly differentiated gastric cancer
Table 1 Expression of Cyr-61 and COX-2 in gastric carcinoma a
and non-tumor tissues
Group Gastric cancer Non-tumor gastric mucosa p
Cyr-61 0.008
High expression 50 (60.98 %) 15 (34.88 %)
Low expression 32 (39.02 %) 28 (65.12 %)
COX-2 0.038
High expression 51 (62.20 %) 18 (41.86 %)
Low expression 31 (37.80 %) 25 (58.14 %)
Abbreviations: Cyr-61 cysteine-rich 61, COX-2 cyclooxygenase-2
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43 non-tumor gastric mucosa specimens, and the results
demonstrated the clinical significance of the expressions
of Cyr-61 and COX-2 in determining the clinicopatho-
logic features of gastric cancer and predicting its prog-
nostic value.
Our results showed that Cyr-61 expression in gastric
cancer tissues was significantly higher than that in the
non-tumor gastric mucosa tissues. Furthermore, gastric
cancer with higher Cyr-61 expression was associated
with stronger invasion and metastasis abilities, advanced
TNM stage and shorter survival time, suggesting that
Cyr-61 plays an important role in the progression of gas-
tric cancer. These results were consistent with the find-
ings of Lin et al. [15]. They found Cyr-61 expression
level was closely related to stages of gastric cancers,
lymph node metastasis, and histological type. The 5-year
survival time of patients with high Cyr-61 expression
was significantly shorter than that of patients with low
Cyr-61 expression [15]. Their further study also showed
that cell lines had higher level of Cyr-61 expression, ac-
companied by significantly higher adhesion ability than
those showed lower Cyr-61 expression level [19].
Epidemiological studies, clinical and animal trials all
suggested that selective inhibition of COX-2 expression
could reduce the incidence of colorectal cancer [20, 21].
Leung et al. [22] found that there was a link between
mutations in tumor suppressor gene p53 and COX-2 ex-
pression in gastric cancers. Specifically, COX-2 expres-
sion was significantly increased in gastric cancer tissues
with p53 mutation. Coincidently, higher rate of lymph
node metastasis and lower survival rate were evidenced
in gastric cancer with p53 mutation and high COX-2 ex-
pression. In addition, Min et al. [23] found that COX-2
expression in gastric cancers was positively correlated
with the expression of oncogene K-ras, while both gene
expressions were correlated with the depth of tumor
Table 2 Relationship between Cyr-61/COX-2 protein levels and clinicopathologic features of patients with gastric cancer
Characteristic Number Cyr-61 COX-2
High Low p High Low p
Diameter of tumor 0.190 0.003
≥4 58 38 20 42 16
<4 24 12 12 9 15
Infiltration depth 0.027 <0.001
T1 4 1 3 1 3
T2 24 10 14 7 17
T3 25 17 8 20 5
T4 29 22 7 23 6
Lymph node metastasis 0.001 < 0.001
Yes 56 41 15 42 14
No 26 9 17 9 17
Distance metastasis 0.045 0.017
Yes 23 18 5 19 4
No 59 32 27 32 27
Histological grade 0.031 0.015
I 17 6 11 7 10
II 22 13 9 11 11
III 43 31 12 33 10
Gender 0.752 0.971
Male 58 36 22 36 22
Female 24 14 10 15 9
TNM stage 0.009 < 0.001
I 19 6 13 3 16
II 13 7 6 8 5
III 25 17 8 20 5
IV 25 20 5 20 5
Abbreviations: Cyr-61 cysteine-rich 61, COX-2 cyclooxygenase-2, TNM tumour node metastasis
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invasion and rate of lymphatic metastasis. Our results
showed that COX-2 expression in gastric cancers was
significantly different from that in the non-tumor gastric
mucosa. In addition, COX-2 expression was significantly
associated with tumor size, depth of invasion, rate of
lymph node metastasis, distant metastasis, and patho-
logical stage of the tumor. Furthermore, patients with
high COX-2 expression revealed decreased survival time.
Cyr-61 had been reported to mediate extensive cellular
processes, including cell adhesion, cell motility, cell
invasion, cell survival, and cell proliferation [24–26]. Lin
et al. [19] suggested that Cyr-61 might promote the adhe-
sion ability of gastric tumor cells through up-regulating
the functional integrin α2β1 via an AP-1-dependent
signaling pathway, therefore, contribute to the peritoneal
dissemination of gastric cancer [19]. Furthermore, Lin et
al. [27] found that Cyr-61 could enhance gastric cancer
cell invasion by promoting the expression of hypoxia-
inducible factor-1 (HIF-1). Interestingly, COX-2, an im-
portant rate-limiting enzyme in prostaglandin synthesis,
Fig. 3 Kaplan-Meier curves for survival analyses. a, Kaplan-Meier curves for cum survivals of Cyr-61 expression. b, Kaplan-Meier curves for cum
survivals of COX-2 expression. c, Kaplan-Meier curves for cum survivals of combined expression of Cyr-61 and COX-2
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had been demonstrated to promote angiogenesis by in-
creasing the expression of HIF-1 in gastric carcinoma
[28]. It had been confirmed that COX-2 was closely asso-
ciated with gastric carcinoma progression through regulat-
ing tumor proliferation, apoptosis, invasiveness and
angiogenesis [29, 30]. Through clinical trials and in vitro
experiments, Lin et al. [15] further confirmed that COX-2
was a downstream gene induced by Cyr-61, and Cyr-61
could affect the invasion ability of gastric cancer cells by
upregulating COX-2 activity via the αVβ3/NF-kB pathway.
These results indicated that the Cyr-61 and COX-2 might
have a synergistic promoting effect on the progression of
gastric carcinoma. Therefore, we speculated that the
higher prognostic value of combined expression of Cyr-61
and COX-2 than Cyr-61 or COX-2 alone might be caused
by the synergistic mechanism in the progression of gastric
cancer.
Undoubtedly, our study has several limitations. The
first limitation is the small sample and the retrospective
nature of this study, more prospective studies with larger
sample size should be performed to confirm the results
of this study. Second, because the data are retrospect-
ively collected, no available data can be used to confirm
the prognostic value of combined expression of Cyr-61
and COX-2 by receiver operating characteristic curve.
Third, the current study only compared the Cyr-61/COX-
2 protein levels between the GC tissues and non-tumor
tissues, while the both detections of COX-2 and Cyr-61
RNA and protein levels may be more comprehensive. In
addition, we only chose one technique (immunohisto-
chemistry) in this study; however, the conclusions may be
more convincing if we supplemented the data of Western
blot or in situ hybridization. Fourth, because immunohis-
tochemical figures cannot be exactly distinguish cell types,
we did not describe the cell types of COX2 and Cyr-
61expressions. Lastly, there is no mechanism study in this
study, further investigations for the downstream signaling
pathways of Cyr-61/COX-2 and their interaction in gastric
cancer are necessary.
Conclusions
In conclusion, both Cyr-61 and COX-2 expression are
associated with the progression of gastric cancer. Mean-
while, prognostic role of Cyr-61 and COX-2 is confirmed
in this study. Moreover, combined expression of Cyr-61
and COX-2 has higher prognostic value than single
expression for the survival of gastric cancer patients.
Abbreviations
CI, confidence interval; COX-2, cyclooxygenase-2; Cyr-61/CCN1, cysteine-rich
61; DAB, diaminobenzidine; HR, hazard ratio; TNM, tumor node metastasis
Acknowledgements
The authors are grateful to the Surgery Department and the Endoscopy
Center of Shengjing Hospital of China Medical University for the Gastric
cancer specimens and non-cancerspecimens.




Table 3 Cox proportional hazard regression model analyses of whole cohort
Univariate Multivariatea Multivariateb
HR (95 % CI) p HR (95 % CI) p HR (95 % CI) p
Gender 0.316 0.968 0.704
Male 1 1 1
Female 0.7 (0.3–1.5) 1.1 (0.4–2.5) 0.8 (0.3–2.07)
Histological grade 0.031 0.563 0.697
Grade I-II 1 1 1
Grade III 2.2 (1.08–4.5) 1.2 (0.6–2.6) 1.2 (0.6–2.4)
Cyr-61 expression < 0.001 0.008 -
Low 1 1
High 6.9 (2.6–18.04) 4.1 (1.5–11.6)
COX-2 expression < 0.001 0.039 -
Low 1 1
High 5.6 (2.4–13.03) 2.9 (1.06–7. 8)
Combined expression of Cyr-61 and COX-2 0.001 - 0.003
Both low 1 1
One low 18.2 (2.3–142.7) 0.006 17.9 (2.2–143.3) 0.006
Both high 34.8 (4.6–262.4) 0.001 31.8 (4.09–246.8) 0.001
Abbreviation: HR hazard ratio, CI confidence interval; amultivariate Cox regression analysis including sex, histological grade, Cyr-61 expression and COX-2 expression;
bmultivariate Cox regression analysis including sex, histological grade, and combined expression of Cyr-61 and COX-2
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